β, β-Dimethylacrylshikonin potentiates paclitaxel activity, suppresses immune evasion and triple negative breast cancer progression via STAT3Y705 phosphorylation inhibition based on network pharmacology and transcriptomics analysis

Bai, 2021, Cinobufagin suppresses colorectal cancer growth via STAT3 pathway inhibition, Am. J. Cancer Res., 11, 200 Bardia, 2021, Sacituzumab govitecan in metastatic triple-negative breast cancer, N. Engl. J. Med., 384, 1529, 10.1056/NEJMoa2028485 Berger, 2009, Network analyses in systems pharmacology, Bioinformatics, 25, 2466, 10.1093/bioinformatics/btp465 Chang, 2013, The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis, Neoplasia, 15, 848, 10.1593/neo.13706 Chen, 2002, Cellular pharmacology studies of shikonin derivatives, Phytother. Res., 16, 199, 10.1002/ptr.1100 Chen, 2019, Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling, Biochem. Pharmacol., 166, 33, 10.1016/j.bcp.2019.05.001 Cong, 2020, Tim-3 promotes cell aggressiveness and paclitaxel resistance through NF-κB/STAT3 signalling pathway in breast cancer cells, Chin. J. Cancer Res., 32, 564, 10.21147/j.issn.1000-9604.2020.05.02 Dave, 2012, Epithelial-mesenchymal transition, cancer stem cells and treatment resistance, Breast Cancer Res., 14, 202, 10.1186/bcr2938 Earnshaw, 1999, Mammalian caspases: structure, activation, substrates, and functions during apoptosis, Annu. Rev. Biochem., 68, 383, 10.1146/annurev.biochem.68.1.383 Falamarzian, 2014, Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy, J. Biomed. Mater. Res. A, 102, 3216, 10.1002/jbm.a.34992 Fan, 2012, Effect of β,β-dimethylacrylshikonin on inhibition of human colorectal cancer cell growth in vitro and in vivo, Int. J. Mol. Sci., 13, 9184, 10.3390/ijms13079184 Foulkes, 2010, Triple-negative breast cancer, N. Engl. J. Med., 363, 1938, 10.1056/NEJMra1001389 Hata, 2019, Targeting MUC1-C inhibits TWIST1 signaling in triple-negative breast cancer, Mol. Cancer Ther., 18, 1744, 10.1158/1535-7163.MCT-19-0156 Jiang, 2019, Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies, Cancer Cell, 35, 428, 10.1016/j.ccell.2019.02.001 Kilkenny, 2010, Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research, PLoS Biol., 8, 10.1371/journal.pbio.1000412 Liu, 2022, The FUS/circEZH2/KLF5/feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition, Mol. Cancer, 21, 198, 10.1186/s12943-022-01653-2 Malorni, 2012, Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up, Breast Cancer Res. Treat, 136, 795, 10.1007/s10549-012-2315-y Marotta, 2011, The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors, J. Clin. Investig., 121, 2723, 10.1172/JCI44745 Peinado, 2007, Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?, Nat. Rev. Cancer, 7, 415, 10.1038/nrc2131 Qin, 2019, STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review, J. Exp. Clin. Cancer Res., 38, 195, 10.1186/s13046-019-1206-z Wang, 2015, β, β-Dimethylacrylshikonin induces mitochondria-dependent apoptosis of human lung adenocarcinoma cells in vitro via p38 pathway activation, Acta Pharmacol. Sin., 36, 131, 10.1038/aps.2014.108 Wu, 2012, Inhibitory effects of β,β-dimethylacrylshikonin on hepatocellular carcinoma in vitro and in vivo, Phytother. Res., 26, 764, 10.1002/ptr.3623 Xiong, 2013, Apoptosis induced by β,β-dimethylacrylshikonin is associated with Bcl-2 and NF-κB in human breast carcinoma MCF-7 cells, Oncol. Lett., 6, 1789, 10.3892/ol.2013.1613 Xuan, 2009, Naturally-occurring shikonin analogues–a class of necroptotic inducers that circumvent cancer drug resistance, Cancer Lett., 274, 233, 10.1016/j.canlet.2008.09.029 Zerdes, 2019, STAT3 activity promotes programmed-death ligand 1 expression and suppresses immune responses in breast cancer, Cancers, 11 Zhen-Jun, 2012, β,β-Dimethylacrylshikonin exerts antitumor activity via Notch-1 signaling pathway in vitro and in vivo, Biochem. Pharmacol., 84, 507, 10.1016/j.bcp.2012.05.013 Zou, 2023, The Single-cell landscape of intratumoral heterogeneity and the immunosuppressive microenvironment in liver and brain metastases of breast cancer, Adv. Sci., 10, 10.1002/advs.202203699